Artelo Biosciences reports positive preclinical data for ART27.13 in paclitaxel-induced peripheral neuropathy model
ARTL•Preclinical results in neuropathy model
Artelo Biosciences reported positive nonclinical results for ART27.13 in a paclitaxel-induced peripheral neuropathy model.
Repeated dosing reduced neuropathic pain behaviors, including mechanical allodynia and thermal hyperalgesia, in male and female animals.
Potential expansion into oncology supportive care
The data supports potential expansion into oncology supportive care for chemotherapy-induced neuropathic pain, beyond its Phase 2 CACS program.
Interim CAReS Phase 2 findings showed trends toward improved body weight, lean body mass and activity, with favorable safety up to 1,300 µg/day.
Pain endpoints were added to CAReS to assess whether the analgesic signal translates clinically.
